A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials
While racial diversity in PCa clinical trials remains an unsolved problem, there are significant opportunities to better address this unmet need. Through a multi-perspective approach to identify key barriers that limit Black and African American enrollment in PCa clinical trials, we developed recommendations for both sponsors and clinical trial sites to increase diverse patient enrollment in PCa clinical trials, with a focus on employing practical strategies.
Authors
- Jones T. Nauseef (ORCID: https://orcid.org/0000-0003-2302-4171)
- Shane McDevitt (ORCID: https://orcid.org/0000-0001-9360-2841)
- Stanley K. Frencher
- Paul Leger
- Alan S. Brown (ORCID: https://orcid.org/0000-0001-6445-2821)
- Brian Jones (ORCID: https://orcid.org/0000-0002-9439-2353)
- Aminha Ullah
- Che‐Kai Tsao
- Mehmet Asim Bilen
Institutions
- Emory University (US)
- Bayer (United States) (US)
- Georgetown University (US)
- Cornell University (US)
- Georgetown University Medical Center (US)
- Prostate Cancer Foundation (US)
- Cancer Institute (WIA) (IN)
- Martin Luther King, Jr. Community Hospital (US)
- Weill Cornell Medicine (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1080/14796694.2025.2467519
- Citations
- 1
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 1.88